| Indicators | Browse All

Vyome Holdings, Inc. (HIND)

Healthcare | Biotechnology | Cambridge, United States | NasdaqCM
2.24 USD -0.01 (-0.444%) ⇩ (July 13, 2026, 4 p.m. EDT)

Short-term:★☆☆☆☆Long-term:⯪☆☆☆☆Dividends:☆☆☆☆☆
Hot Take | July 11, 2026, 3 a.m. EDT

The immediate outlook is severely clouded by a brutal multi-year price collapse, with the stock down nearly 100% over the last eight years and suffering four consecutive years of negative annual returns. This relentless downward trajectory suggests the market has thoroughly rejected the current business model, rendering any short-term bounce highly speculative rather than a genuine trend reversal. Fundamentally, the company is in deep distress, reporting massive revenue contraction of over 84%, negative operating margins exceeding 35%, and negative returns on equity. While the balance sheet currently shows low debt relative to equity, the cash burn is significant, and the lack of any dividend history confirms this is a pure growth-at-any-cost biotech play that has failed to deliver. The recent news of a 'rally' and 'transformational results' appears to be a desperate attempt to stabilize a sinking ship rather than evidence of a turnaround, especially given the stark disconnect between the reported financials and the market's continued punishment of the stock.

Model Selection — Backtest MAE (log-scale, lower is better)
ModelMAE
MSTL ✓0.050655
AutoETS0.051983
AutoTheta0.210696
AutoARIMA0.590726

Forecast horizon: 45 days | Selected: MSTL

Forecast Reliability
Score 43%
H-stat 0.40
Ljung-Box p 0.000
Jarque-Bera p 0.318
Excess Kurtosis -0.55
Attribute Value
Sector Healthcare
Debt to Equity Ratio 0.28
Revenue per Share 0.04
Market Cap 15,721,503
Website https://www.vyometx.com

Info Dump

Attribute Value
52 Week Change -0.7646444
Address1 Harvard Square
Address2 One Mifflin Place Suite 400
All Time High 138,156,000.0
All Time Low 1.75
Ask 2.79
Ask Size 2
Average Daily Volume10 Day 16,220
Average Daily Volume3 Month 27,370
Average Volume 27,370
Average Volume10Days 16,220
Bid 2.21
Bid Size 1
Book Value 0.961
City Cambridge
Compensation As Of Epoch Date 1,767,139,200
Country United States
Crypto Tradeable 0
Currency USD
Current Price 2.24
Current Ratio 4.273
Custom Price Alert Confidence HIGH
Date Short Interest 1,782,777,600
Day High 2.24
Day Low 2.2
Debt To Equity 0.28
Display Name Vyome
Earnings Timestamp End 1,763,064,000
Earnings Timestamp Start 1,763,064,000
Ebitda -3,666,912
Ebitda Margins 0.0
Enterprise To Ebitda -2.249
Enterprise To Revenue 53.99
Enterprise Value 8,245,614
Eps Trailing Twelve Months -1.55
Esg Populated 0
Exchange NCM
Exchange Data Delayed By 0
Exchange Timezone Name America/New_York
Exchange Timezone Short Name EDT
Fifty Day Average 2.1517
Fifty Day Average Change 0.08829999
Fifty Day Average Change Percent 0.041037314
Fifty Two Week Change Percent -76.46444
Fifty Two Week High 18.6
Fifty Two Week High Change -16.36
Fifty Two Week High Change Percent -0.8795699
Fifty Two Week Low 1.75
Fifty Two Week Low Change 0.49
Fifty Two Week Low Change Percent 0.28
Fifty Two Week Range 1.75 - 18.6
Financial Currency USD
First Trade Date Milliseconds 1,475,760,600,000
Float Shares 3,254,351
Free Cashflow 4,116,844
Full Exchange Name NasdaqCM
Full Time Employees 9
Gmt Off Set Milliseconds -14,400,000
Gross Margins 0.53034997
Gross Profits 80,997
Has Pre Post Market Data 1
Held Percent Insiders 0.52881
Held Percent Institutions 0.0152199995
Implied Shares Outstanding 7,018,528
Industry Biotechnology
Industry Disp Biotechnology
Industry Key biotechnology
Is Earnings Date Estimate 1
Language en-US
Last Fiscal Year End 1,767,139,200
Last Split Date 1,755,216,000
Last Split Factor 1:4
Long Business Summary Vyome Holdings, Inc., a clinical-stage specialty pharmaceutical company, develops therapeutic products targeting immuno-inflammatory and rare diseases in the United States. It operates through Pharmaceutical and Biotechnology segments. The company's lead product candidate VT-1953, a dual DNA Gyrase/Topoisomerase inhibitor and immunomodulator in a topical gel formulation that is in phase 2 clinical stage for the treatment of bacterial conjunctivitis. It also develops VT-1908, a topical eye drop is an inosine 5'-monophosphate dehydrogenase enzyme inhibitor to treat immunoinflammatory conditions of the eye; and VB-1953, which is in phase 2 clinical stage for the treatment of inflammatory acne. In addition, the company develops antifungal products using the molecular replacement therapy (MRT) platform. It has a collaboration and license agreement with Sun Pharma Laboratories Limited to develop and commercialize next-generation antifungal products. The company is based in Cambridge, Massachusetts.
Long Name Vyome Holdings, Inc.
Market us_market
Market Cap 15,721,503
Market State PRE
Max Age 86,400
Message Board Id finmb_115222623
Most Recent Quarter 1,774,915,200
Net Income To Common -10,930,943
Next Fiscal Year End 1,798,675,200
Non Diluted Market Cap 15,791,688
Number Of Analyst Opinions 2
Open 2.22
Operating Cashflow -4,981,284
Operating Margins -35.76778
Payout Ratio 0.0
Phone 973-832-8147
Previous Close 2.25
Price Hint 4
Price To Book 2.3309052
Price To Sales Trailing12 Months 102.94062
Profit Margins 0.0
Quick Ratio 4.168
Quote Source Name Nasdaq Real Time Price
Quote Type EQUITY
Recommendation Key none
Region US
Regular Market Change -0.00999999
Regular Market Change Percent -0.444444
Regular Market Day High 2.24
Regular Market Day Low 2.2
Regular Market Day Range 2.2 - 2.24
Regular Market Open 2.22
Regular Market Previous Close 2.25
Regular Market Price 2.24
Regular Market Time 1,783,972,801
Regular Market Volume 15,162
Return On Assets -0.39536
Return On Equity -6.65567
Revenue Growth -0.841
Revenue Per Share 0.04
Sand P52 Week Change 0.20847368
Sector Healthcare
Sector Disp Healthcare
Sector Key healthcare
Shares Outstanding 7,018,528
Shares Percent Shares Out 0.005
Shares Short 35,140
Shares Short Previous Month Date 1,780,012,800
Shares Short Prior Month 77,671
Short Name Vyome Holdings, Inc.
Short Percent Of Float 0.0078
Short Ratio 1.63
Source Interval 15
State MA
Symbol HIND
Target High Price 15.0
Target Low Price 8.0
Target Mean Price 11.5
Target Median Price 11.5
Total Cash 8,795,783
Total Cash Per Share 1.253
Total Debt 22,548
Total Revenue 152,724
Tradeable 0
Trailing Annual Dividend Rate 0.0
Trailing Annual Dividend Yield 0.0
Trailing Eps -1.55
Trailing Peg Ratio None
Triggerable 1
Two Hundred Day Average 3.344285
Two Hundred Day Average Change -1.104285
Two Hundred Day Average Change Percent -0.3302006
Type Disp Equity
Volume 15,162
Website https://www.vyometx.com
Zip 2,138